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1. INTRODUCTION {#acel13089-sec-0001}
===============

Glaucoma is comprised of progressive optic neuropathies characterized by degeneration of retinal ganglion cells (RGC) and resulting changes in the optic nerve. It is a complex disease where multiple genetic and environmental factors interact (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}; Weinreb, Aung, & Medeiros, [2014](#acel13089-bib-0026){ref-type="ref"}). Two of the leading risk factors, increased intraocular pressure (IOP) and age, are related to the extent and rate of RGC loss. Although lowering IOP is the only approved and effective treatment for slowing worsening of vision, many treated glaucoma patients continue to experience loss of vision and some eventually become blind. Several findings suggest that age‐related physiological tissue changes contribute significantly to neurodegenerative defects that cause result in the loss of vision.

Mammalian aging is a complex process where distinct molecular processes contribute to age‐related tissue dysfunction. It is notable that specific molecular processes underlying RGC damage in aging eyes are poorly understood. While no single defect defines aging, several lines of evidence suggest that activation of senescence is a vital contributor (He & Sharpless, [2017](#acel13089-bib-0012){ref-type="ref"}).

In a mouse model of glaucoma/ischemic stress, we reported the effects of *p16Ink4a* on RGC death (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Upon increased IOP, the expression of *p16Ink4a* was elevated, and this led to enhanced senescence in RGCs and their death. Such changes most likely cause further RGC death and directly cause loss of vision. In addition, the analysis of p16KO mice suggested that lack of *p16Ink4a* gene protected RGCs from cell death caused by elevated IOP (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Importantly, elevated expression of *p16INK4a* and senescence were both detected in human glaucomatous eyes (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Therefore, for the first time, *p16Ink4a* was implicated as a downstream integrator of diverse signals causing RGC aging and death, both characteristics changes in the pathogenesis of glaucoma. Our findings were further supported by a subsequent report showing that *p16Ink4a* was upregulated by TANK binding kinase 1 (TBK1) a key regulator of neuroinflammation, immunity, and autophagy activity. TBK also caused RGC death in ischemic retina injury (Li, Zhao, & Zhang, [2017](#acel13089-bib-0016){ref-type="ref"}). Of particular note, a recent bioinformatic meta‐analysis of a published set of genes associated with primary open‐angle glaucoma (POAG) pointed at senescence and inflammation as key factors in RGC degeneration in glaucoma (Danford et al., [2017](#acel13089-bib-0009){ref-type="ref"}).

Glaucoma remains relatively asymptomatic until it is severe, and the number of affected individuals is much higher than the number diagnosed. Numerous clinical studies have shown that lowering IOP slows the disease progression (Boland et al., [2013](#acel13089-bib-0003){ref-type="ref"}; Sihota, Angmo, Ramaswamy, & Dada, [2018](#acel13089-bib-0024){ref-type="ref"}). However, RGC and optic nerve damage are not halted despite lowered IOP, and deterioration of vision progresses in most treated patients. This suggests the possibility that an independent damaging agent or process persists even after the original insult (elevated IOP) has been ameliorated.

We hypothesized that early removal of senescent RGCs that secrete senescent associated secretory proteins (SASP) could protect remaining RGCs from senescence and death induced by IOP elevation. To test this hypothesis, we used an established transgenic p16‐3MR mouse model (Demaria et al., [2014](#acel13089-bib-0010){ref-type="ref"}) in which the systemic administration of the small molecule ganciclovir (GCV) selectively kills *p16INK4a*‐expressing cells. We show that the early removal of *p16Ink4^+^* cells has a strong protective effect on RGC survival and visual function. We confirm the efficiency of the method by showing the reduced level of *p16INK4a* expression and lower number of senescent β‐galactosidase‐positive cells after GCV treatment. Finally, we show that treatment of p16‐3MR mice with a known senolytic drug (dasatinib) has a similar protective effect on RGCs as compared to GCV treatment in p16‐3MR mice.

2. MATERIALS AND METHODS {#acel13089-sec-0002}
========================

2.1. Animals {#acel13089-sec-0003}
------------

All animal experiments were approved by the UC San Diego Institutional Animal Care and Use Committee (IACUC) and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Adult p16‐3MR (Demaria et al., [2014](#acel13089-bib-0010){ref-type="ref"}) or C57BL/6 mice (12--16 weeks old, Jackson Labs) were housed in 20°C environment with standard (12 hr light/dark) cycling, food, and water available ad libitum. For all experiments, an equal number of male and female mice were used.

2.2. Drug treatment {#acel13089-sec-0004}
-------------------

The p16‐3MR transgenic model (Figure [1](#acel13089-fig-0001){ref-type="fig"}a), in which the mice carry a trimodal reporter protein (3MR) under the control of p16 regulatory region (Demaria et al., [2014](#acel13089-bib-0010){ref-type="ref"}), allows potent selective removal of senescent cells. The 3MR transgene encodes a fusion protein consisting of Renilla luciferase, a monomeric red fluorescent protein (mRFP) and herpes simplex virus thymidine kinase (HSV‐TK) which converts ganciclovir (GCV) into a toxic DNA chain terminator to selectively kill HSV‐TK expressing cells. The experimental group of animals was treated by intraperitoneal (IP) administration of GCV (Sigma, 25 mg/kg once a day) or dasatinib (Sigma, 5 mg/kg) after IOP elevation (see below), and a control group of mice was sham‐treated with PBS or vehicle (DMSO). Each mouse underwent unilateral hydrostatic pressure‐induced IOP elevation to 90 mm Hg, with the contralateral eye left as an untreated control. The mice were IP injected intraperitoneally with GCV or dasatinib at day 0 (IOP elevation day) and continued for four consecutive days (Figure [1](#acel13089-fig-0001){ref-type="fig"}b). At day 5, animals were euthanized, and retinas were isolated and immunostained with anti‐Brn3a antibody to evaluate the number of RGCs. All drugs were prepared according to the UC San Diego Institutional Animal Care and Use Committee (IACUC) standards. To ensure a sterile environment, compounds were prepared under the tissue culture hood using sterile PBS. The final solution was filtered through a 0.22‐µm PES membrane just before injection. Tips, tubes, and syringes were sterile.

![Removal of early senescent cells has a neuroprotective effect on RGCs. (a) Schematic representation of the p16‐3MR transgene. Triple fusion of luciferase, the red fluorescent protein, and tyrosine kinase from HSV virus are under control of the regulatory region of p16Ink4a gene. (b) Plan of the experiment. After unilateral IOP elevation mice are daily injected with GCV (25 mg/kg) intraperitoneally. At day 5 VEP is measured, and tissue is collected for further experiments. (c) Representative images of retina flat‐mount immunohistochemistry at day five with anti‐Brn3a antibody specifically labeling \~80% of RGC cells. (d) Quantification of RGC number at day five after the treatment of WT animals. *N* ≥ 5 animals in each group (e) Quantification of RGC number at day five after the treatment of p163MR animals. *N* = 8 animals in each group. In d and e, statistical tests were performed using ANOVA with post hoc Tukey correction for multiple testing. \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001, n.s., not significant](ACEL-19-e13089-g001){#acel13089-fig-0001}

2.3. Hydrostatic intraocular pressure (IOP) elevation {#acel13089-sec-0005}
-----------------------------------------------------

Animals were anesthetized with an intraperitoneal injection of ketamine/xylazine cocktail, (100 and 10 mg/kg, respectively), their eyes anesthetized with one drop of proparacaine (0.5%, Bausch‐Lomb) and dilated with one drop of tropicamide (1%, Alcon Laboratories). Unilateral elevation of IOP was achieved by infusing balanced salt solution (Alcon Laboratories) into the anterior chamber of the eye through using an intravenous (IV) infusion set. The level of IOP increase was determined by the height of the saline bottles on the IV infusion set. Stable elevated IOP of 85--90 mm Hg was maintained for 60 min and controlled by IOP measurements using a veterinary rebound tonometer (Tonovet). Both eyes were lubricated throughout testing with an ophthalmic lubricant gel (GenTeal, Alcon Laboratories). Animals recovered on a Deltaphase isothermal pad (Braintree Scientific) until awake. The contralateral eye without IOP elevation served as a healthy non‐IOP control (CTRL).

2.4. Visual evoked potential {#acel13089-sec-0006}
----------------------------

VEP measurements were taken at five days post‐IOP elevation. This protocol was adapted from prior studies (Ridder & Nusinowitz, [2006](#acel13089-bib-0021){ref-type="ref"}). Mice were dark‐adapted for at least 12 hr before the procedure. Animals were anesthetized with ketamine/xylazine and their eyes dilated as above. The top of the mouse\'s head was cleaned with an antiseptic solution. A scalpel was used to incise the scalp skin, and a metal electrode was inserted into the primary visual cortex through the skull, 0.8 mm deep from the cranial surface, 2.3 mm lateral to the lambda. A platinum subdermal needle (Grass Telefactor) was inserted through the animal\'s mouth as a reference and through the tail as ground. The measurements commenced when the baseline waveform became stable, 10--15 s after attaching the electrodes. Flashes of light at 2 log cd.s/m^2^ were delivered through a full‐field Ganzfeld bowl at 2 Hz. Signal was amplified, digitally processed by the software (Veris Instruments), then exported, and peak‐to‐peak responses were analyzed in Excel (Microsoft). To isolate VEP of the measured eye from the crossed signal originating in the contralateral eye, a black aluminum foil eyepatch was placed over the eye not undergoing measurement. For each eye, peak‐to‐peak response amplitude of the major component P1‐N1 in IOP eyes was compared to that of their contralateral non‐IOP controls. Following the readings, the animals were euthanized, and their eyes collected and processed for immunohistological analysis.

2.5. Immunohistochemistry {#acel13089-sec-0007}
-------------------------

Following euthanasia, eyes were enucleated and fixed in 4% paraformaldehyde (PFA) in PBS (Affymetrix) for 1 hr and subsequently transferred to PBS. The eyes were then dissected, the retinas flat‐mounted on microscope slides, and immunostained using a standard sandwich assay with anti‐Brn3a antibodies (Millipore, MAB1595) and secondary AlexaFluor 555 anti‐mouse (Invitrogen, A32727). Mounted samples (Fluoromount, Southern Biotech 0100‐01) were imaged in the fluorescent microscope at 20x magnification (Biorevo BZ‐X700, Keyence), focusing on the central retina surrounding the optic nerve. Overall damage and retina morphology were also taken into consideration for optimal assessment of the retina integrity. Micrographs were quantified using manufacturer software for Brn3a‐positive cells in 6 independent 350 × 350 µm areas per flat mount.

2.6. Real‐time PCR {#acel13089-sec-0008}
------------------

Total RNA extraction from mouse tissues, cDNA synthesis, and RT‐qPCR experiments were performed as previously described (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Assays were performed in triplicate. Relative mRNA levels were calculated by normalizing results using GAPDH. The primers used for RT‐qPCR are the same as in (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). The differences in quantitative PCR data were analyzed with an independent two‐sample *t* test.

2.7. SA‐βgal assay to test senescence on retinas mouse eyes {#acel13089-sec-0009}
-----------------------------------------------------------

Senescence assays were performed using the Senescence b‐Galactosidase Staining Kit (Cell Signaling) according to the manufacturer\'s protocol. Images were acquired using a Hamamatsu Nanozoomer 2.0HT Slide Scanner and quantified in independent images of 0.1 mm^2^ covering the areas of interest using Keyence software.

2.8. RNA‐Seq analysis {#acel13089-sec-0010}
---------------------

High‐quality RNA was extracted using TRIzol Reagent (Invitrogen) and treated with TURBO DNA‐free Kit (Invitrogen). RNA‐Seq libraries were made from 1 µg total RNA per tissue sample using TruSeq stranded mRNA Library Prep Kit (Illumina, kit cat. no. 20020597) according to the manufacturer\'s instructions. The libraries were size‐selected using Agencourt Ampure XP beads (Beckman Coulter) and quality‐checked by Bioanalyzer (Agilent). The strand‐specific RNA‐Seq paired‐end reads sequence data (PE50: 2 × 50 bp) were obtained on a HiSeq4000. RNA‐Seq reads were counted using HOMER software considering only exonic regions for RefSeq genes.

3. RESULTS {#acel13089-sec-0011}
==========

Intraocular pressure was increased in one eye of transgenic mice bearing the p16‐3MR construct (Figure [1](#acel13089-fig-0001){ref-type="fig"}a). After IOP elevation, mice were intraperitoneally injected with GCV for five consecutive days (Figure [1](#acel13089-fig-0001){ref-type="fig"}b) to specifically deplete p16Ink4a‐positive (p16^+^) cells. In parallel, wild‐type animals were subjected to the same protocol, that is, underwent five daily GCV injections after unilateral IOP elevation. Retina flat‐mount immunohistochemistry and RGC quantification were used to assess potential impact of drug treatment. We observed that five‐day administration of GCV after IOP elevation had a significant protective effect on Brn3a^+^ RGC number in p16‐3MR mice when compared to untreated eye (Figure [1](#acel13089-fig-0001){ref-type="fig"}c,[1](#acel13089-fig-0001){ref-type="fig"}). This protection was not observed in WT animals (Figure [1](#acel13089-fig-0001){ref-type="fig"}e) confirming that the effect of the GCV injection is specific to the mice harboring the GCV‐sensitive transgene.

Next, to test whether the protection of RGC numbers in GCV‐treated retinas was accompanied by the protection of the visual circuit integrity on day five, the in vivo signal transmission from the retina to the primary visual cortex was assessed by measuring visual evoked potentials (VEP) (Figure [2](#acel13089-fig-0002){ref-type="fig"}a)(Bui & Fortune, [2004](#acel13089-bib-0005){ref-type="ref"}; Porciatti, [2015](#acel13089-bib-0020){ref-type="ref"}). In brief, the reading electrode was placed in the striate visual cortex, with the reference electrode in the animal\'s mouth and ground electrode in the tail. Flash stimuli were presented in a Ganzfeld bowl. Response amplitudes were quantified from the peak‐to‐peak analysis of the first negative component N1. Using this approach, we have found that eyes subjected to IOP elevation showed decreased VEP P1‐N1 amplitude (Figure [2](#acel13089-fig-0002){ref-type="fig"}b), compared to contralateral non‐IOP control eyes. However, there was a marked rescue of VEP signals in transgenic animals treated with GCV (Figure [2](#acel13089-fig-0002){ref-type="fig"}b). Further quantification showed significant vision rescue upon GCV treatment only in p16‐3MR and not WT animals (Figure [2](#acel13089-fig-0002){ref-type="fig"}c,[2](#acel13089-fig-0002){ref-type="fig"}), confirming the specificity of GCV treatment.

![Visual functions are preserved in animals when senescent cells were removed. (a) Schematic representation of the placement of electrodes for VEP measurements. (b) Example results of VEP experiments. Top: results of the VEP response of healthy and IOP‐treated eyes. Bottom: After GCV injections, the VEP response is protected. (c) Quantification of VEP responses at day five after the treatment of WT animals. *N *≥ 4, (d) Quantification of VEP responses at day 5 after the treatment of the p16‐3MR animals. *N *≥ 6. In c and d, statistical tests were performed using ANOVA with post hoc Tukey correction for multiple testing. \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001, n.s., not significant](ACEL-19-e13089-g002){#acel13089-fig-0002}

Our previous studies indicated that the increase in *p16INK4a* expression could be first observed as early as day three post‐IOP elevation (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Therefore, we chose this time‐point to analyze the effectiveness of GCV treatment on senescent cells in treated and control retinas of p16‐3MR animals. RGC quantification showed that in animals not injected with GCV only \~15%--20% of cells disappeared at day 3 (compared to \~45%--50% on day 5).

To test whether GCV treatment indeed removed senescent cells in the retina, we used two approaches. First, we quantified the *p16Ink4a* expression at day three post IOP treatment in GCV‐treated and control retinas. Expectedly, GCV treatment prevented IOP‐induced increase in *p16Ink4a* expression observed in non treated eyes (Figure [3](#acel13089-fig-0003){ref-type="fig"}b). Importantly, this was accompanied by significant decrease in numbers of IOP‐induced β‐galactosidase‐positive senescent cells in 3‐day GCV treated retinas as compared to nontreated cells (Figure [3](#acel13089-fig-0003){ref-type="fig"}c,[3](#acel13089-fig-0003){ref-type="fig"}). This indicates that IOP‐induced early senescent cells are efficiently removed by GCV treatment by day 3, what precedes the RGC loss observed in non‐treated eyes between day 3 and day 5.

![Senescence is lowered upon GCV treatment \~2 days before the effects on RGC numbers are observed. (a) At day 3 after IOP, only 20% of RGCs are lost compared to the non‐treated eye. Similar numbers of cells are lost in GCV‐treated eyes at this stage. *N* = 3 (non‐GCV) and *N* = 5 (GCV), ANOVA, \**p* \< .05, \*\**p* \< .01, n.s. -- not significant (b) p16Ink4a expression is significantly lower in affected retinas isolated from GCV‐treated p16‐3MR animals at day 3 after IOP elevation. t‐test, \*\**p* \< .01 (c) Number of SA‐b‐gal positive cells is lowered upon GCV treatment. Blue arrow -- remaining senescent cell (d). Quantification of number of senescent cells upon IOP elevation in retinas isolated from mouse treated and non‐treated with GCV. *N* = 4 (non‐GCV), *N* = 6 (GCV); ANOVA, \*\**p* \< .01](ACEL-19-e13089-g003){#acel13089-fig-0003}

We next set forward on trying to understand molecular changes underlying the apparent protective effect of the removal of senescent cells by GCV treatment in p16‐3MR animals.

First, we performed time‐course experiment in wild‐type mice to follow the activation of caspase expression as a marker of endogenous stress in the cell (Figure [4](#acel13089-fig-0004){ref-type="fig"}a). We quantified both total number of RGC (by nuclear staining for RGC specific transcription factor Brn3a) and activated caspase‐positive cells (by phospho‐caspase 3 staining). The highest number of RGCs with concomitant staining of activated caspase was observed at day 3 after IOP elevation (Figure [4](#acel13089-fig-0004){ref-type="fig"}a *right*). As shown above, at day 3 most of the RGCs are still present (Figure [3](#acel13089-fig-0003){ref-type="fig"}a). Day 3 also corresponds to the highest expression levels of senescence‐associated factors, as previously observed (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). We thus reasoned that relevant effects of GCV treatment should be easy to observe at around this stage. To identify potential differences in an unbiased way, we performed RNA‐seq analysis in IOP and non‐IOP retinas with or without GCV treatment. Total RNA isolated from 3 retinas in each experimental group was converted to cDNA libraries and sequenced. Of the total 21,351 detected gene loci, 1601 were significantly de‐regulated by the IOP treatment; 999 detected gene loci were up regulated; and 602 down‐regulated (Figure [4](#acel13089-fig-0004){ref-type="fig"}b, *top*). When the IOP treatment was performed in mice treated with GCV, the total numbers of IOP‐affected genes changed modestly to 1707, with 848 up regulated and 859 down‐regulated (Figure [4](#acel13089-fig-0004){ref-type="fig"}b, *bottom*).

![Analysis of pathways affected in IOP‐treated retinas. (a) Immunohistochemistry of Brn3a and activated caspase show increase of apoptosis at days1, 2 and 3 after IOP treatment. left: quantification of the time‐course experiments followed by immunochemistry with Brn3a and activated caspase 3; (b) RNA‐seq analysis of response to IOP and GCV. Eyes subjected to IOP elevation show significant change in gene expression with more genes upregulated than downregulated. Similar analysis in GCV‐treated animals shows close to equal distribution of upregulated and downregulated genes c. Heatmap analysis of genes involved in senescence, active oxidative species (ROS), apoptosis, extracellular matrix homeostasis (ECM), and inflammation. (d) Venn diagram showing overlap between genes dysregulated upon IOP in GCV‐treated and GCV‐untreated retinas. A total of 617 genes specifically dysregulated in IOP only retinas were used for GO analysis](ACEL-19-e13089-g004){#acel13089-fig-0004}

To inquire in an unbiased way about the differences in signaling pathways and cellular processes affected by IOP, GO analysis using PANTHER was performed (Mi, Muruganujan, Ebert, Huang, & Thomas, [2019](#acel13089-bib-0017){ref-type="ref"}). This approach revealed that processes of the immune system response, inflammation, and extracellular matrix composition and cell--matrix interaction were significantly changed in IOP samples (Table [1](#acel13089-tbl-0001){ref-type="table"}). We have also detected the significantly deregulated genes involved in apoptosis, microglial activation and interlukin‐6 and interlukin‐8 production and secretion. This analysis shows that many mechanisms are induced upon an acute IOP elevation, most probably causing additional transcriptional stress to cell.

###### 

List of pathways specifically deregulated in retinas upon IOP treatment

+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Analysis type:                                                                                     | PANTHER Overrepresentation Test (Released 20190517) |    |      |    |       |          |          |
|                                                                                                    |                                                     |    |      |    |       |          |          |
| Annotation version and release date:                                                               | GO Ontology database Released 2019‐02‐02            |    |      |    |       |          |          |
|                                                                                                    |                                                     |    |      |    |       |          |          |
| Analyzed list:                                                                                     | upload_1 (Mus musculus)                             |    |      |    |       |          |          |
|                                                                                                    |                                                     |    |      |    |       |          |          |
| Reference list:                                                                                    | Mus musculus (all genes in database)                |    |      |    |       |          |          |
|                                                                                                    |                                                     |    |      |    |       |          |          |
| Test type:                                                                                         | FISHER                                              |    |      |    |       |          |          |
|                                                                                                    |                                                     |    |      |    |       |          |          |
| Correction:                                                                                        | FDR                                                 |    |      |    |       |          |          |
+====================================================================================================+=====================================================+====+======+====+=======+==========+==========+
| Cellular response to interferon‐gamma (GO:0071346)                                                 | 100                                                 | 17 | 2.48 | \+ | 6.85  | 3.36E−09 | 2.94E−07 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of interleukin−6 production (GO:0032755)                                       | 95                                                  | 14 | 2.36 | \+ | 5.94  | 3.91E−07 | 2.40E−05 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Protein ADP‐ribosylation (GO:0006471)                                                              | 27                                                  | 8  | 0.67 | \+ | 11.95 | 1.48E−06 | 7.66E−05 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of gliogenesis (GO:0014015)                                                    | 84                                                  | 11 | 2.08 | \+ | 5.28  | 1.88E−05 | 7.29E−04 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Lens development in camera‐type eye (GO:0002088)                                                   | 69                                                  | 10 | 1.71 | \+ | 5.84  | 2.05E−05 | 7.83E−04 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of wound healing (GO:0090303)                                                  | 55                                                  | 9  | 1.36 | \+ | 6.6   | 2.25E−05 | 8.56E−04 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of tyrosine phosphorylation of STAT protein (GO:0042509)                                | 70                                                  | 10 | 1.74 | \+ | 5.76  | 2.29E−05 | 8.70E−04 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Response to interleukin−1 (GO:0070555)                                                             | 87                                                  | 11 | 2.16 | \+ | 5.1   | 2.53E−05 | 9.54E−04 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular response to interleukin‐1 (GO:0071347)                                                    | 72                                                  | 10 | 1.79 | \+ | 5.6   | 2.85E−05 | 1.06E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of superoxide anion generation (GO:0032930)                                    | 20                                                  | 6  | 0.5  | \+ | 12.1  | 2.98E−05 | 1.10E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Integrin‐mediated signaling pathway (GO:0007229)                                                   | 73                                                  | 10 | 1.81 | \+ | 5.52  | 3.17E−05 | 1.16E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Respiratory burst (GO:0045730)                                                                     | 13                                                  | 5  | 0.32 | \+ | 15.51 | 5.38E−05 | 1.90E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of cytokine‐mediated signaling pathway (GO:0001960)                            | 48                                                  | 8  | 1.19 | \+ | 6.72  | 5.72E−05 | 2.00E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular response to cadmium ion (GO:0071276)                                                      | 23                                                  | 6  | 0.57 | \+ | 10.52 | 5.78E−05 | 2.01E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of interleukin‐6 production (GO:0032715)                                       | 49                                                  | 8  | 1.22 | \+ | 6.58  | 6.52E−05 | 2.23E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630)                       | 81                                                  | 10 | 2.01 | \+ | 4.98  | 7.05E−05 | 2.40E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of intracellular transport (GO:0032387)                                        | 66                                                  | 9  | 1.64 | \+ | 5.5   | 8.11E−05 | 2.71E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of response to wounding (GO:1903035)                                           | 84                                                  | 10 | 2.08 | \+ | 4.8   | 9.30E−05 | 3.05E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Lens fiber cell development (GO:0070307)                                                           | 15                                                  | 5  | 0.37 | \+ | 13.44 | 9.35E−05 | 3.06E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| negative regulation of response to cytokine stimulus (GO:0060761)                                  | 52                                                  | 8  | 1.29 | \+ | 6.2   | 9.47E−05 | 3.09E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of cell‐matrix adhesion (GO:0001953)                                           | 38                                                  | 7  | 0.94 | \+ | 7.43  | 9.57E−05 | 3.11E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Synapse pruning (GO:0098883)                                                                       | 7                                                   | 4  | 0.17 | \+ | 23.04 | 9.78E−05 | 3.16E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Protein poly‐ADP‐ribosylation (GO:0070212)                                                         | 7                                                   | 4  | 0.17 | \+ | 23.04 | 9.78E−05 | 3.16E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Lens fiber cell differentiation (GO:0070306)                                                       | 26                                                  | 6  | 0.64 | \+ | 9.3   | 1.04E−04 | 3.33E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of macrophage activation (GO:0043030)                                                   | 53                                                  | 8  | 1.31 | \+ | 6.09  | 1.07E−04 | 3.40E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Mononuclear cell migration (GO:0071674)                                                            | 39                                                  | 7  | 0.97 | \+ | 7.24  | 1.11E−04 | 3.51E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of homotypic cell--cell adhesion (GO:0034110)                                           | 29                                                  | 6  | 0.72 | \+ | 8.34  | 1.75E−04 | 5.14E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of ERK1 and ERK2 cascade (GO:0070373)                                          | 75                                                  | 9  | 1.86 | \+ | 4.84  | 1.96E−04 | 5.72E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of myeloid leukocyte mediated immunity (GO:0002887)                            | 9                                                   | 4  | 0.22 | \+ | 17.92 | 2.04E−04 | 5.89E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| I‐kappaB kinase/NF‐kappaB signaling (GO:0007249)                                                   | 45                                                  | 7  | 1.12 | \+ | 6.27  | 2.44E−04 | 6.80E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Iron ion transport (GO:0006826)                                                                    | 45                                                  | 7  | 1.12 | \+ | 6.27  | 2.44E−04 | 6.82E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of interleukin−8 production (GO:0032677)                                                | 61                                                  | 8  | 1.51 | \+ | 5.29  | 2.56E−04 | 7.04E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of endothelial cell migration (GO:0010595)                                     | 97                                                  | 10 | 2.41 | \+ | 4.16  | 2.73E−04 | 7.38E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of calcium‐mediated signaling (GO:0050848)                                              | 97                                                  | 10 | 2.41 | \+ | 4.16  | 2.73E−04 | 7.39E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Protein mono‐ADP‐ribosylation (GO:0140289)                                                         | 10                                                  | 4  | 0.25 | \+ | 16.13 | 2.80E−04 | 7.52E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of neuron apoptotic process (GO:0043525)                                       | 79                                                  | 9  | 1.96 | \+ | 4.59  | 2.79E−04 | 7.52E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Protein auto‐ADP‐ribosylation (GO:0070213)                                                         | 11                                                  | 4  | 0.27 | \+ | 14.66 | 3.75E−04 | 9.63E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902041)        | 49                                                  | 7  | 1.22 | \+ | 5.76  | 3.89E−04 | 9.93E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Protein transport within lipid bilayer (GO:0032594)                                                | 49                                                  | 7  | 1.22 | \+ | 5.76  | 3.89E−04 | 9.95E−03 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Acute inflammatory response (GO:0002526)                                                           | 66                                                  | 8  | 1.64 | \+ | 4.89  | 4.15E−04 | 1.06E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of hypersensitivity (GO:0002885)                                               | 12                                                  | 4  | 0.3  | \+ | 13.44 | 4.90E−04 | 1.21E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Interleukin−6‐mediated signaling pathway (GO:0070102)                                              | 12                                                  | 4  | 0.3  | \+ | 13.44 | 4.90E−04 | 1.22E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of wound healing (GO:0061045)                                                  | 68                                                  | 8  | 1.69 | \+ | 4.74  | 4.98E−04 | 1.23E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of interleukin−10 production (GO:0032653)                                               | 52                                                  | 7  | 1.29 | \+ | 5.43  | 5.38E−04 | 1.31E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Negative regulation of receptor signaling pathway via JAK‐STAT (GO:0046426)                        | 24                                                  | 5  | 0.6  | \+ | 8.4   | 5.99E−04 | 1.42E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Microglial cell activation (GO:0001774)                                                            | 24                                                  | 5  | 0.6  | \+ | 8.4   | 5.99E−04 | 1.43E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Response to lipoprotein particle (GO:0055094)                                                      | 24                                                  | 5  | 0.6  | \+ | 8.4   | 5.99E−04 | 1.43E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of interleukin−12 production (GO:0032655)                                               | 53                                                  | 7  | 1.31 | \+ | 5.33  | 5.96E−04 | 1.43E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Tolerance induction (GO:0002507)                                                                   | 13                                                  | 4  | 0.32 | \+ | 12.41 | 6.29E−04 | 1.49E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of tyrosine phosphorylation of STAT protein (GO:0042531)                       | 55                                                  | 7  | 1.36 | \+ | 5.13  | 7.28E−04 | 1.69E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular defense response (GO:0006968)                                                             | 14                                                  | 4  | 0.35 | \+ | 11.52 | 7.93E−04 | 1.82E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular extravasation (GO:0045123)                                                                | 40                                                  | 6  | 0.99 | \+ | 6.05  | 8.05E−04 | 1.83E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of cell adhesion mediated by integrin (GO:0033628)                                      | 40                                                  | 6  | 0.99 | \+ | 6.05  | 8.05E−04 | 1.84E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular response to lipoprotein particle stimulus (GO:0071402)                                    | 26                                                  | 5  | 0.64 | \+ | 7.75  | 8.23E−04 | 1.87E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Monoamine transport (GO:0015844)                                                                   | 26                                                  | 5  | 0.64 | \+ | 7.75  | 8.23E−04 | 1.87E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Response to hydrogen peroxide (GO:0042542)                                                         | 94                                                  | 9  | 2.33 | \+ | 3.86  | 8.93E−04 | 1.99E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of membrane invagination (GO:1905155)                                          | 15                                                  | 4  | 0.37 | \+ | 10.75 | 9.85E−04 | 2.16E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of hypersensitivity (GO:0002883)                                                        | 15                                                  | 4  | 0.37 | \+ | 10.75 | 9.85E−04 | 2.16E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular response to low‐density lipoprotein particle stimulus (GO:0071404)                        | 15                                                  | 4  | 0.37 | \+ | 10.75 | 9.85E−04 | 2.17E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of vascular endothelial cell proliferation (GO:1905564)                        | 15                                                  | 4  | 0.37 | \+ | 10.75 | 9.85E−04 | 2.17E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of release of sequestered calcium ion into cytosol (GO:0051279)                         | 79                                                  | 8  | 1.96 | \+ | 4.08  | 1.22E−03 | 2.58E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of interleukin−6 secretion (GO:2000778)                                        | 29                                                  | 5  | 0.72 | \+ | 6.95  | 1.27E−03 | 2.66E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of phosphatidylinositol 3‐kinase activity (GO:0043552)                         | 29                                                  | 5  | 0.72 | \+ | 6.95  | 1.27E−03 | 2.66E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of type I interferon production (GO:0032479)                                            | 80                                                  | 8  | 1.98 | \+ | 4.03  | 1.32E−03 | 2.74E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771) | 31                                                  | 5  | 0.77 | \+ | 6.5   | 1.65E−03 | 3.33E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Cellular response to amyloid‐beta (GO:1904646)                                                     | 31                                                  | 5  | 0.77 | \+ | 6.5   | 1.65E−03 | 3.33E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Toll‐like receptor signaling pathway (GO:0002224)                                                  | 47                                                  | 6  | 1.17 | \+ | 5.15  | 1.71E−03 | 3.42E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Inflammatory response to wounding (GO:0090594)                                                     | 8                                                   | 3  | 0.2  | \+ | 15.12 | 2.01E−03 | 3.89E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of cell adhesion mediated by integrin (GO:0033630)                             | 19                                                  | 4  | 0.47 | \+ | 8.49  | 2.08E−03 | 3.98E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of glial cell differentiation (GO:0045687)                                     | 49                                                  | 6  | 1.22 | \+ | 4.94  | 2.08E−03 | 3.98E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Glial cell activation (GO:0061900)                                                                 | 33                                                  | 5  | 0.82 | \+ | 6.11  | 2.12E−03 | 3.99E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of lipid kinase activity (GO:0090218)                                          | 33                                                  | 5  | 0.82 | \+ | 6.11  | 2.12E−03 | 4.00E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of epithelial cell apoptotic process (GO:1904035)                                       | 87                                                  | 8  | 2.16 | \+ | 3.71  | 2.15E−03 | 4.06E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Actin cytoskeleton reorganization (GO:0031532)                                                     | 68                                                  | 7  | 1.69 | \+ | 4.15  | 2.25E−03 | 4.21E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Response to axon injury (GO:0048678)                                                               | 34                                                  | 5  | 0.84 | \+ | 5.93  | 2.38E−03 | 4.41E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Regulation of oxidative stress‐induced neuron intrinsic apoptotic signaling pathway (GO:1903376)   | 9                                                   | 3  | 0.22 | \+ | 13.44 | 2.64E−03 | 4.73E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Amyloid fibril formation (GO:1990000)                                                              | 9                                                   | 3  | 0.22 | \+ | 13.44 | 2.64E−03 | 4.76E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Hydrogen peroxide biosynthetic process (GO:0050665)                                                | 9                                                   | 3  | 0.22 | \+ | 13.44 | 2.64E−03 | 4.76E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Response to amyloid‐beta (GO:1904645)                                                              | 35                                                  | 5  | 0.87 | \+ | 5.76  | 2.67E−03 | 4.76E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Neuroinflammatory response (GO:0150076)                                                            | 35                                                  | 5  | 0.87 | \+ | 5.76  | 2.67E−03 | 4.76E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Toll‐like receptor 3 signaling pathway (GO:0034138)                                                | 9                                                   | 3  | 0.22 | \+ | 13.44 | 2.64E−03 | 4.77E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Actin‐myosin filament sliding (GO:0033275)                                                         | 9                                                   | 3  | 0.22 | \+ | 13.44 | 2.64E−03 | 4.77E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
| Positive regulation of acute inflammatory response (GO:0002675)                                    | 35                                                  | 5  | 0.87 | \+ | 5.76  | 2.67E−03 | 4.77E−02 |
+----------------------------------------------------------------------------------------------------+-----------------------------------------------------+----+------+----+-------+----------+----------+
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Further analysis revealed that the genes involved in cellular senescence, extracellular matrix molecules and in factors involved in apoptosis (Table [2](#acel13089-tbl-0002){ref-type="table"}) (Pawlikowski *et al.*, [2013](#acel13089-bib-0019){ref-type="ref"}) were significantly de regulated upon IOP elevation. Importantly, 3‐day treatment to remove p16 + cells significantly mitigated this response (Figure [4](#acel13089-fig-0004){ref-type="fig"}c). These data are in agreement with the loss of the senescence cells upon GCV treatment (Figure [3](#acel13089-fig-0003){ref-type="fig"}b[3](#acel13089-fig-0003){ref-type="fig"}) and lower detrimental impact of senescent cells on surrounding cells.

###### 

List of genes in pathways represented in Figure [4](#acel13089-fig-0004){ref-type="fig"}c

  Apoptosis   ECM       SASP
  ----------- --------- -----------
  Abl1        Adamts1   Ang5
  Actb        Adamts2   Areg
  Aifm1       Adamts5   Ccl11
  Akt1        Adamts8   Ccl12
  Anxa5       Cdh1      Ccl2
  Apaf1       Cdh2      Ccl20
  Api5        Cdh3      Ccl7
  Atf5        Cdh4      Csf2
  Bag1        Cntn1     Csf3
  Bag3        Col1a1    Ctsb
  Bak1        Col2a1    Cxcl11
  Bax         Col3a1    Cxcl12
  Bcl10       Col4a1    Cxcl13
  Bcl2a1a     Col4a2    Egf
  Bcl2l10     Col4a3    Egfr
  Bcl2l2      Col5a1    Ereg
  Bid         Col6a1    Fas
  Birc2       Ctgf      Fgf2
  Birc3       Ctnna1    Fgf7
  Birc5       Ctnna2    Fn1
  Bnip2       Ctnnb1    Hgf
  Bok         Ecm1      Icam1
  Card10      Emilin1   Ifng
  Casp1       Entpd1    Igfbp2
  Casp12      Fbln1     Igfbp3
  Casp14      Fn1       Igfbp4
  Casp2       Hapln1    Igfbp5
  Casp3       Hc        Igfbp6
  Casp4       Icam1     Igfbp7
  Casp6       Itga2     Il13
  Casp7       Itga3     Il15
  Casp8       Itga4     Il1a
  Casp9       Itga5     Il1b
  Cd40lg      Itgae     Il6
  Cd70        Itgal     Il6st
  Cflar       Itgam     Il7
  Cidea       Itgav     Mip
  Cideb       Itgb1     Mmp12
  Cradd       Itgb2     Mmp13
  Dad1        Itgb3     Mmp14
  Dapk1       Itgb4     Mmp1a
  Dffa        Lama1     Mmp2
  Dffb        Lama2     Mmp3
  Diablo      Lama3     Mmp7
  Fas         Lamb2     Mmp9
  Fasl        Lamb3     Ngf
  Gadd45a     Lamc1     Pigf
  Gapdh       Mmp10     Plaur
  Gusb        Mmp11     Serpinb2
  Hsp90ab1    Mmp13     Serpine1
  Igf1r       Mmp14     Timp1
  Il10        Mmp15     Timp2
  Lhx4        Mmp1a     Tnfrsf11b
  Ltbr        Mmp2      Tnfrsf1a
  Mapk1       Mmp3      Tnfrsf1b
  Mcl1        Mmp7      Tnfrsf22
  Naip1       Mmp8       
  Naip2       Mmp9       
  Nfkb1       Ncam1      
  Nme5        Ncam2      
  Nod1        Pecam1     
  Nol3        Postn      
  Polb        Sele       
  Prdx2       Sell       
  Ripk1       Selp       
  Tnfrsf10b   Sgce       
  Tnfrsf11b   Sparc      
  Tnfrsf1a    Spock1     
  Tnfsf10     Spp1       
  Tnfsf12     Syt1       
  Traf1       Tgfbi      
  Traf2       Thbs1      
  Trp53       Thbs2      
  Trp53bp2    Thbs3      
  Trp63       Timp1      
  Trp73       Timp2      
  Xiap        Timp3      
              Tnc        
              Vcam1      
              Vcan       
              Vtn        
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Additional GO analysis of the 617 genes which were significantly de regulated upon IOP elevation specifically in non treated retinas (i.e., genes where the effects of IOP were dampened by GCV‐mediated removal of senescent cells) (Figure [4](#acel13089-fig-0004){ref-type="fig"}d) identified a specific enrichment of a class of genes belonging to the ABL1 pathway and ABL1 downstream targets (Fig. [S1](#acel13089-sup-0001){ref-type="supplementary-material"}). Prompted by this finding, we explored whether dasatinib, a well‐known senolytic drug and a Bcr‐Abl and Src family threonine kinase inhibitor, could have a beneficial effect similar to GCV in p16‐3MR mice. To this end, p16‐3MR mice were treated with dasatinib (5 mg/kg) or vehicle for 5 days by intraperitoneal injection, similarly to the experimental procedure used for GCV (Figure [1](#acel13089-fig-0001){ref-type="fig"}b). Performing this experiment in the transgenic mice allowed direct comparison of the efficiencies of both treatments in the same mouse strain. At day five after IOP elevation, VEP measurement was performed and retinas were immunostained to quantify RGC loss. We observed that dasatinib treatment prevented the loss of RGC (Figure [5](#acel13089-fig-0005){ref-type="fig"}c) similar to what was observed in GCV‐treated animals (Figure [1](#acel13089-fig-0001){ref-type="fig"}e). Most importantly, VEP analysis revealed that senolytic drug treatment successfully prevented vision loss upon IOP elevation (Figure [5](#acel13089-fig-0005){ref-type="fig"}d).

![Dasatinib protects retina degeneration. (a) Plan of the experiment. After unilateral IOP elevation, mice are daily injected with dasatinib (5 mg/kg) intraperitoneally. At day 5, VEP is measured and tissue is collected for further experiments. Immunohistochemistry of Brn3a and activated caspase show increase of apoptosis at day 3 after IOP treatment. (b) Retina flat‐mount immunohistochemistry at day 5 with anti‐Brn3a antibody specifically labeling \~80% of RGC cells. (c,d) Quantification of RGC number (c) or VEP responses (d) at day 5 (four conditions) or day 12 (additional 7 days of "recovery," two conditions) after the 5 days treatment of p16‐3MR animals with dasatinib. *N* \> 4 animals in each group. Statistical tests were performed using ANOVA with post hoc Tukey correction for multiple testing. \**p* \< .05, \*\*\**p* \< .001, n.s. -- not significant (e). Model. Top: Upon elevated IOP damaged cells become senescent and start to express SASP molecules. While disease progresses, the SASP molecule induces senescence or apoptosis in neighboring cells. Bottom: When senescent cells are removed using senolytic drug the neighboring cells are not exposed to detrimental SASPs and the disease progression is significantly slowed down. Remaining cells are healthy](ACEL-19-e13089-g005){#acel13089-fig-0005}

Finally, we explored whether the protective impact of the drug is caused by the sustained inhibition of the cellular processes and whether it is maintained even after the drug is no longer present. To do that, p16‐3MR mice were treated with dasatinib (5 mg/kg) or vehicle for 5 days by intraperitoneal injection, similarly to the experimental procedure used for GCV (Figure [1](#acel13089-fig-0001){ref-type="fig"}b). After that, the mice were no longer treated with drug or PBS and at day twelve after IOP elevation, functional measurement was performed and RGCs were quantified. Also in this treatment regime, dasatinib prevented the loss of RGC (Figure [5](#acel13089-fig-0005){ref-type="fig"}c) similar to what was observed in GCV‐treated animals (Figure [1](#acel13089-fig-0001){ref-type="fig"}e). Additionally, VEP analysis revealed that senolytic drug treatment with seven days "chase" still successfully prevented vision loss upon IOP elevation (Figure [5](#acel13089-fig-0005){ref-type="fig"}d).

4. DISCUSSION {#acel13089-sec-0012}
=============

The collective findings of the current study strongly support the notion that removal of senescent cells provides beneficial protective effect to retinas damaged by elevated IOP. Here, we show that in transgenic animals expressing viral TK under the control of regulatory regions of p16Ink4a (Demaria et al., [2014](#acel13089-bib-0010){ref-type="ref"}), selective removal of early senescent cells in the retina is beneficial for neighboring cells undergoing cellular stress induced by IOP elevation. In this model, the treatment with GCV selectively induces cell death of transgene‐expressing cells. Early application of GCV as soon as day 0 after the IOP elevation and followed for five consecutive days ensures early removal of *p16Ink4a* expressing cells resulting in protection of neighboring RGCs from death. Remaining cells are still able to provide a signal to the visual cortex, as evidenced by VEP measurements, demonstrating that protected cells are functional.

Three days after GCV injection, there is a significant drop in senescent cell number and an accompanying alteration of the transcriptional programs in remaining cells as compared to retinas from untreated mice. Using an RNA‐seq approach, we noted significant changes in the senescence program as well as in the extracellular matrix (ECM) function. Both pathways are downregulated by GCV treatment. Finally, we show that dasatinib, a known senolytic drug, can be used to protect RGCs from death, further confirming that early removal of senescent cells induced upon IOP elevation protects retina health. The observation also was confirmed when the RGC count and VEP were assessed seven days after the treatment was stopped; this suggests that the impact of the drug is not reversible during this time. Further studies should investigate different regimes and dosages of the senolytic drugs and their neuroprotective role in particular to investigate the efficiency in the removal of senescent cells from the tissue.

Taken together, the results prompt us to propose a model of how increased IOP leads to the destruction of retinal structures during glaucoma progression (Figure [5](#acel13089-fig-0005){ref-type="fig"}e). During early stages, elevated IOP induces cell‐intrinsic changes leading to cellular senescence and production of SASP. As the disease worsens, SASP molecules induce apoptosis and senescence in neighboring cells. Such changes are largely independent of whether the initial insult is still present or has been eliminated with IOP‐lowering treatment. RGC apoptosis inevitably leads to the loss of axons and optic nerve degeneration. Conversely, when senescent cells (induced directly by elevated IOP) are removed using senolytic drugs (Figure [5](#acel13089-fig-0005){ref-type="fig"}e, *bottom*), neighboring cells are not exposed to detrimental SASP and remain healthy. We propose that such treatment can lead reduce the rate of glaucoma worsening. Moreover, we speculate that changes in combination with IOP‐lowering treatments may have even better protection than either type of therapy alone.

We and others previously used 90 mm Hg as an extremely acute and reproducible way to induce cell response and RGC death (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). This level of pressure is likely an ischemic insult. The resulting synchronized and quick cell death provide unique qualities that are extremely useful for molecular and biochemical studies; however such an acute and high‐pressure change is not fully representative of POAG, a chronic optic neuropathy. However, this acute insult allows the study of stress response time course and can help unravel important aspects of stepwise response of retinal cells to elevated IOP which is a daunting task to assess in chronic models the disease. Importantly, our previous data showing the presence of senescent cells in human glaucomatous retinas (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}) should stimulate the use of senolytic drugs in other animal models of glaucoma.

Dasatinib is a selective tyrosine kinase receptor inhibitor that is commonly used in the therapy of chronic myelogenous leukemia (CML). Other studies have shown that treatment with dasatinib is effective in destroying senescent fat cell precursors (Zhu et al., [2015](#acel13089-bib-0029){ref-type="ref"}). Our RNA‐seq data pointed to this senolytic drug as a potential candidate for in vivo treatment of retinal damage induced by IOP elevation. Notably, we found that the level of RGC protection resembles the one obtained with GCV treatment of p16‐3MR transgenic line. Based on these findings, we conclude that dasatinib treatment resulted in RGC protection through removal of senescent cells. It will be of interest to further investigate the possible therapeutic effects of other senolytic drugs in glaucoma and glaucoma models.

The gene encoding *p16INK4a*, *CDKN2A*, lies within the INK4/ARF tumor suppressor locus on human chromosome 9p21; this is the most significant region to be identified as having an association with POAG in different population samples (Ng, Casson, Burdon, & Craig, [2014](#acel13089-bib-0018){ref-type="ref"}). Although the molecular mechanism of many of these associations is yet to be described, we have shown that one of them especially highly correlates with the presence of another top risk variant of glaucoma---Six6 rs33912345. Our study further showed that upregulation of homozygous *SIX6* risk alleles (CC) leads to an increase in *p16Inka* expression, with subsequent cellular senescence (Skowronska‐Krawczyk et al., [2015](#acel13089-bib-0025){ref-type="ref"}). Interestingly, others have described an alternative mechanism whereby IOP‐induced TBK1 expression caused an increase of *p16Ink4a* expression through the Akt‐ Bmi1 phosphorylation pathway (Li et al., [2017](#acel13089-bib-0016){ref-type="ref"}). Given the complexity of the 9p21 locus, we believe that there are more pathways involved in *p16Ink4a* regulation and further work is needed to understand the role of p16Ink4a as a integrator of these signals especially upon IOP elevation.

Several collaborative efforts identified numerous SNPs localized within the 9p21 locus to be highly associated with the risk of open‐angle glaucoma including normal‐tension glaucoma (NTG), a glaucomatous optic neuropathy not associated with elevated IOP (Killer & Pircher, [2018](#acel13089-bib-0014){ref-type="ref"}; Wiggs & Pasquale, [2017](#acel13089-bib-0027){ref-type="ref"}). Intriguingly, one of the top variants associated with the risk of NTG is located in the gene TBK1, a factor that has been recently shown to be implicated in upregulation of *p16ink4a* gene (Li et al., [2017](#acel13089-bib-0016){ref-type="ref"}). Finally, recent studies have also revealed that specific methylation patterns in the 9p21 locus are strongly associated with the risk of NTG glaucoma (Burdon, [2018](#acel13089-bib-0006){ref-type="ref"}). It is notable that the positions of most, if not all, of these SNPs and methylation markers overlap with active regulatory regions within the locus identified by ENCODE (Consortium, [2012](#acel13089-bib-0008){ref-type="ref"}). Although regulation of the 9p21 locus in the context of many diseases and aging is under extensive investigation, it still remains to be explicitly addressed in relation to glaucoma.

Another major type of glaucomatous optic neuropathy is angle closure glaucoma (ACG), a condition characterized by blockage of the drainage angle of the eye. To date, there is no study reporting genetic variants or methylation markers in the 9p21 locus significantly associated with the risk of ACG despite several studies implicating various molecular mechanisms (Evangelho, Mogilevskaya, Losada‐Barragan, & Vargas‐Sanchez, [2019](#acel13089-bib-0011){ref-type="ref"}). Nevertheless, the fact that progressive vision loss is observed in PACG patients, even after lowering the IOP (Brubaker, [1996](#acel13089-bib-0004){ref-type="ref"}), raises the question whether an association could be observed between 9p21 markers and the *progression* rather than the *risk* of the disease. Further studies to unravel such associations are necessary.

Markers of cellular senescence such as expression of the *p16Ink4a* and SASP molecules dramatically increase during aging in both humans and mice. Several studies suggest that *p16Ink4a* + cells act to shorten healthy lifespan by promoting age‐dependent changes that functionally impair tissues and organs (Baker et al., [2016](#acel13089-bib-0001){ref-type="ref"}; Childs et al., [2016](#acel13089-bib-0007){ref-type="ref"}; Jeon et al., [2017](#acel13089-bib-0013){ref-type="ref"}; Krishnamurthy et al., [2006](#acel13089-bib-0015){ref-type="ref"}). Intriguingly, a recent explosion of studies has shown that removal of senescent cells using senolytic drugs in progeroid (accelerated aging phenotype) and healthy mice induces lifespan extension and improves the health of animals (Baker et al., [2011](#acel13089-bib-0002){ref-type="ref"}, [2016](#acel13089-bib-0001){ref-type="ref"}; Scudellari, [2017](#acel13089-bib-0023){ref-type="ref"}; Xu et al., [2018](#acel13089-bib-0028){ref-type="ref"}). Our studies suggest a potential use of such therapy to reduce glaucoma associated blindness, either as a stand‐alone treatment or together with IOP‐lowering therapies.
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